In the original article, there was a mistake in Table 3 as published. The administration form of satralizumab is “SC” not “IV.” The corrected Table 3 appears below.
Table 3.
Immunosuppressive molecules for attack prevention in NMOSD.
| Monoclonal antibody | Mechanism | Route | Risk | |
|---|---|---|---|---|
| Rituximab | Chimeric | CD20-B cell depletion | IV | Infections; Hepatitis B reactivation; Infusion-related reaction |
| Eculizumab | Humanized | C5 complement inhibitor | IV | Meningococcal infection; Possible PML risk; Infusion-related reaction |
| Satralizumab | Humanized recycling | IL-6 receptor blocker | SC | |
| Tocilizumab | Humanized | IL-6 receptor blocker | SC | Cardiovascular risk; Cholesterol levels |
| Inebelizumab | Humanized | CD19-B cell depletion | IV | Infections; Infusion-related reaction |
| Ofatumumab | Fully humanized | CD20-B cell depletion | SC | Infections; Infusion-related reaction; Hepatitis B reactivation |
| Ocrelizumab | Humanized | CD20-B cell depletion | IV | Infections; Infusion-related reaction; Hepatitis B reactivation |
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.